BioSpace News Archive

BioMidwest

Lilly’s tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks

Detailed results from Eli Lilly and Company’s phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in Nature Medicine and simultaneously presented at ObesityWeek® 2023.

October 15, 2023
·
13 min read
Bio NC

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Pharma Inc. will share new research results during the European Society for Medical Oncology Congress 2023 from October 20-24, showcasing the company’s focus on making a meaningful difference for people living with hard-to-treat cancers.

October 15, 2023
·
8 min read
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases

October 15, 2023
·
14 min read
Biotech Bay

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

GE HealthCare announced new data from a pilot study conducted with Cleveland Clinic evaluating the Portrait Mobile wireless and wearable monitoring solution.

October 15, 2023
·
6 min read
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023

ImCheck Therapeutics announced that updated data from its ongoing Phase I/IIa clinical trial EVICTION will be presented at the European Society for Medical Oncology Congress in an oral session on October 22nd in Madrid.

October 15, 2023
·
7 min read
Bio NC

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Arvinas, Inc. and Pfizer Inc. announced they will present updated Phase 1/2 data for vepdegestrant at the 2023 European Society for Medical Oncology Annual Congress.

October 15, 2023
·
8 min read
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Novocure announced its participation in the European Society for Medical Oncology Congress 2023 from October 20 – 24 in Madrid.

October 15, 2023
·
6 min read
Pharm Country

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. announced the latest clinical data in early- and late-stage cancers from its oncology pipeline will be presented at the European Society for Medical Oncology Congress 2023 from October 20 to 24 in Madrid, Spain.

October 15, 2023
·
19 min read
Policy

Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Burning Rock Biotech Limited is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US FDA for its OverC™ Multi-Cancer Detection Blood Test in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China NMPA.

October 15, 2023
·
2 min read